Epratuzumab and Rituximab Have Different Modes of Action
13th Nov 2006, 16:15 GMT
Immunomedics, a biopharmaceutical company focused on developing monoclonal antibodies, reported that studies have shown that epratuzumab and rituximab have distinct mechanisms of action - epratuzumab acts as an immunomodulatory agent while rituximab is an acutely cytotoxic therapeutic antibody with different modes of action.
Epratuzumab and Rituximab Have Different Modes of Action related news:
- Epratuzumab And Rituximab Have Different Modes Of Action — Health News from Medical News Today
- FDA Allows Resumption of Lupus Trials with Epratuzumab — PR Newswire: All Releases
- New Sketchfighter 4000 Alpha Screenshots — Inside Mac Games
- Action by rail staff called off — Scotsman.com News - Scotland
- Repeat Treatment With MabThera Provides Continuous Improvement Of Quality Of Life In Rheumatoid Arthritis Patients — Health News from Medical News Today
- Zimbabwe: Unity in Action is the Way Forward — AllAfrica News: Editorials
- Cook just gets in to the action — NBA Player News : CBS SportsLine.com
- Tough on the causes of crime — BBC News | Programmes | Law in Action | UK Edition
- Unreal Tournament 2004 Unreal Demolition Public Beta 5 Mod — Gamespot Recent Updates [PC]
- Babcock settles insider dealing action — The Irish Times' Top Stories
Latest news from Bio-Technology News from StratCenter.com:
- IBT Labs Invests $2 mln to Expand Pharmaceutical Services Division
- Mercury Computer Systems Collaborates with Boston Univ to Deliver Biotech Application on the Cell BE Processor
- Nabi Biopharmaceuticals and 3rd Point Reach Agreement
- avVaa World Health Care Products Signs New Spokesman
- China Biopharma Delivers 1.5 mln Doses of Flu Vaccine in China
- Osteologix Appoints Jeremy Curnock Cook to its Board
- Favrille Announces Interim Analysis of Secondary Endpoint from Pivotal Phase 3 Clinical Trial of FavId Following Rituxan in Follicular B-Cell Non-Hodgkin's Lymphoma
- Medarex to Receive Milestone Payment from Amgen
- Arqule Early Cancer Study Shows Progress
- Tanox shares soar in wake of Genentech buyout